Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio ... Business Wire (press release) ... beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |
